Literature DB >> 20047030

Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers.

Mark Day1, J Lynn Rutkowski, Giora Z Feuerstein.   

Abstract

The success rate of novel medical entities that are submitted for registration by the regulatory agencies and followed successful marketing has been stagnating for the past decade. Failure in efficacy and safety continue to be the prime hurdles and causes of failure. Translational medicine is a new function within the pharmaceutical industry R&D organization aimed to improve the predictability and success of drug discovery and development. Biomarkers are the essence of the translational medicine strategy focus on disease biomarker, patient selection, pharmacodynamic responses (efficacy and safety) target validation, compound-target interaction). Successful deployment of biomarkers research, validation and implementation is adopted and embraced as key strategy to improved the drug discovery and development towards new medical entities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20047030     DOI: 10.1007/978-1-4419-1132-2_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

Review 1.  Integrating ADNI results into Alzheimer's disease drug development programs.

Authors:  Jeffrey L Cummings
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

2.  The fourth scientific discovery paradigm for precision medicine and healthcare: Challenges ahead.

Authors:  Li Shen; Jinwei Bai; Jiao Wang; Bairong Shen
Journal:  Precis Clin Med       Date:  2021-04-16

3.  Translational medicine as a permanent glue and force of clinical medicine and public health: perspectives (1) from 2012 Sino-American symposium on clinical and translational medicine.

Authors:  Jiebai Zhou; Duojiao Wu; Xinqing Liu; Shuoqi Yuan; Xiaoqiu Yang; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2012-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.